Overview

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Status:
Active, not recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genmab
Seagen Inc.

Collaborators:

Belgian Gynaecological Oncology Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Genmab
Gynecologic Oncology Group
Merck Sharp & Dohme Corp.
Seattle Genetics, Inc.

Treatments:

Bevacizumab
Carboplatin
Pembrolizumab
Tisotumab vedotin